首页 | 本学科首页   官方微博 | 高级检索  
检索        

南京地区23家医院2006~2008年调脂药利用分析
引用本文:王亚娜,沈健,陈友亮,王淑云,邱召娟,丁琛.南京地区23家医院2006~2008年调脂药利用分析[J].中国药房,2010(26):2412-2414.
作者姓名:王亚娜  沈健  陈友亮  王淑云  邱召娟  丁琛
作者单位:江苏省中医院药剂科,南京市210029
摘    要:目的:评价南京地区23家医院调脂药的应用情况及趋势。方法:对南京市23家医院2006~2008年调脂药的应用品种、销售金额及用药频度进行统计、分析。结果:3年中南京地区医院调脂药销售金额和用药频度逐年增加,主要品种有辛伐他汀、阿托伐他汀、血脂康。结论:他汀类药物在调脂药市场中占主导地位,以阿托伐他汀为代表的"超级他汀"增长迅速,以血脂康为代表的中成药制剂销售前景看好。

关 键 词:调脂药  销售金额  用药频度

Utilization of Lipid-modulating Drugs in 23 Hospitals of Nanjing from 2006 to 2008
WANG Ya-na,SHEN Jian,CHEN You-liang,WANG Shu-yun,QIU Zhao-juan,DING Chen.Utilization of Lipid-modulating Drugs in 23 Hospitals of Nanjing from 2006 to 2008[J].China Pharmacy,2010(26):2412-2414.
Authors:WANG Ya-na  SHEN Jian  CHEN You-liang  WANG Shu-yun  QIU Zhao-juan  DING Chen
Institution:(Dept. of Pharmacy, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing 210029, China)
Abstract:OBJECTIVE:To evaluate the utilization and tendency of lipid-modulating drugs in 23 hospitals of Nanjing. METHODS: The utilization of lipid-modulating drugs in 23 hospitals of Nanjing from 2006 to 2008 was analyzed statistically in terms of drug category, consumption sum and DDDs, etc. RESULTS: The consumption sum and DDDs of lipid-modulating drugs in Nanjing, predominantly simvastatin, atorvastatin, Xuezhikang, increased year by year. CONCLUSION: Statins is the dominant kind of lipid-modulating drugs. The utilization of "super-statins", e.g. atorvastatin, increased rapidly. The prospects for sales of Chinese patent medicine, such as Xuezhikang, will be quite good.
Keywords:Lipid-modulating drugs  Consumption sum  DDDs
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号